Home > Healthcare > Pharmaceuticals > Finished Drug Form > North America and Europe PEGylated Drugs Market
North America and Europe PEGylated Drugs Market Size
- Report ID: GMI2511
- Published Date: Apr 2018
- Report Format: PDF
North America and Europe PEGylated Drugs Market Size
North America & Europe PEGylated Drugs Market size was valued over USD 7.7 billion in 2017 and is expected to witness more than 5% CAGR from 2018 to 2024.
Rising prevalence of chronic diseases including cancer in developed regions coupled with increasing R&D spending by pharmaceutical and biotechnology companies will drive the PEGylated drugs market size. As per American Cancer Society, over 15.5 million Americans are living with cancer and more than 1.7 million new cases are anticipated to be diagnosed in 2018. This will foster demand for PEGylated drugs in the future.
| Report Attribute | Details |
|---|---|
| Base Year: | 2017 |
| North America & Europe PEGylated Drugs Market Size in 2017: | 7.7 Billion (USD) |
| Forecast Period: | 2018 to 2024 |
| Forecast Period 2018 to 2024 CAGR: | 5% |
| 2024 Value Projection: | 10.5 Billion (USD) |
| Historical Data for: | 2013 to 2017 |
| No. of Pages: | 100 |
| Tables, Charts & Figures: | 39 |
| Segments covered: | Disease Indication, Type and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Growing biologics sector such as, new advances in cell therapies, immunotherapies, antibody drug conjugates, gene therapies will offer immense growth opportunities in the future. Increasing acceptance of biologics drugs such as, monoclonal antibodies, colony stimulating factors, and interferons for treatment of chronic diseases will upsurge revenue share of PEGylated drugs in developed regions. However, drug recalls and adverse drug reactions associated with pegylated drugs will hinder business growth during the forecast timeframe.
Frequently Asked Questions (FAQ) :
North America & Europe PEGylated Drugs Market Scope
